Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

Introduction Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We report the efficacy and safety of first-line avel...

Full description

Saved in:
Bibliographic Details
Main Authors: James L Gulley, Jaafar Bennouna, Guy Jerusalem, Janice Mehnert, Matthew Taylor, Karen Kelly, David Spigel, Marcis Bajars, Claire F Verschraegen, Edward F McClay, Nicholas Iannotti, Charles H Redfern, Franklin L Chen, John C Morris, Ding Wang, Hans Juergen Grote, Dongli Zhou, Neru Munshi
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001064.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items